Study #2023-0962
A phase 3, randomized, open-label study to investigate the efficacy and safety of ITK inhibitor Soquelitinib versus physician's choice standard of care treatment (Selected Single Agent) in participants with Relapsed/Refractory peripheral T-cell Lymphoma not otherwise specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-936-4810
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.